tbuckley/cabot-search huggingface dataset:
Engineered mesenchymal stem cell-derived extracellular vesicles: kill tumors and protect organs
Authors: Yu Li, Yao Wang, Yu Zhang, Yuruchen Zhu, Yuhui Dong, Haobin Cheng, Yinan Zhang, Yue Wang, Zhaoshen Li, Jie Gao
Journal: Theranostics (2024)

Solid tumors cause 90% of cancers and remain the primary cause of mortality. However, treating solid tumors presents significant challenges due to the complex tumor microenvironment and drug resistance, leading to inadequate treatment targeting and severe side effects. Surgery, radiotherapy, and chemotherapy Although it is an effective method for the treatment of solid tumors, it can lead to organ dysfunction and affect patient prognosis. Therefore, it is imperative to improve treatment precision and organ repair capabilities to manage solid tumors. Mesenchymal stem cell extracellular vesicles (MSC-EVs) have wide application prospects as a new agent for solid tumor therapy. Firstly, MSC-EVs is a derivative of MSCs. It has the function of promoting tissue regeneration by inducing dedifferentiation in surviving cells after injury. Additionally, MSC-EVs offer unique advantages in terms of safety, stability and penetrability, making them a promising extracellular therapeutic modality for solid tumor treatment. Finally, MSC-EVs are able to enhance therapeutic efficacy through engineering strategies. To sum up, this review takes MSC-EVs as its object. And then we discuss recent advancements and engineering strategies in the use of MSC-EVs for soid tumor suppression. This review aims to inspire researchers to devise a new method for effectively treat solid tumors.
Aspects and prospects of preclinical theranostic radiopharmaceutical development
Authors: Bryce J B Nelson, Viktoria Krol, Aditya Bansal, Jan D Andersson, Frank Wuest, Mukesh K Pandey
Journal: Theranostics (2024)

This article provides an overview of preclinical theranostic radiopharmaceutical development, highlighting aspects of the preclinical development stages that can lead towards a clinical trial. The key stages of theranostic radiopharmaceutical development are outlined, including target selection, tracer development, radiopharmaceutical synthesis, automation and quality control,
Alkaline Phosphatase Controls Lineage Switching of Mesenchymal Stem Cells by Regulating the LRP6/GSK3β Complex in Hypophosphatasia: Erratum
Authors: Wenjia Liu, Liqiang Zhang, Kun Xuan, Chenghu Hu, Liya Li, Yongjie Zhang, Fang Jin, Yan Jin
Journal: Theranostics (2024)

[This corrects the article DOI: 10.7150/thno.27372.].
Preoperative PET imaging and fluorescence-guided surgery of human glioblastoma using dual-labeled antibody targeting ET<sub>A</sub> receptors in a preclinical mouse model: A theranostic approach
Authors: Marie Hautiere, Delphine Vivier, Paul Dorval, Donovan Pineau, Dimitri Kereselidze, Caroline Denis, Amaury Herbet, Narciso Costa, Claire Bernhard, Victor Goncalves, Erwan Selingue, Benoit Larrat, Pierre Alix Dancer, Jean-Philippe Hugnot, Didier Boquet, Charles Truillet, Franck Denat
Journal: Theranostics (2024)

Glioblastoma (GBM) poses significant challenges regarding complete tumor removal due to its heterogeneity and invasiveness, emphasizing the need for effective therapeutic options. In the last two decades, fluorescence-guided surgery (FGS), employing fluorophores such as 5-aminolevulinic acid (5-ALA) to enhance tumor delineation, has gained attraction among neurosurgeons. However, some low-grade tumors do not show any accumulation of the tracers, and the lack of patient stratification represents an important limitation. Since 2000, endothelin axis has been extensively investigated for its role in cancer progression. More specifically, our team has identified endothelin A receptors (ET
SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1
Authors: Meiqian Li, Yangyan Cui, Qi Qi, Jiakuan Liu, Jiaxuan Li, Guifang Huang, Jiale Yang, Jingya Sun, Zhihui Ma, Shengjie Liang, Dianzheng Zhang, Jun Jiang, Rujian Zhu, Qiuli Liu, Ruimin Huang, Jun Yan
Journal: Theranostics (2024)

Cancer cells are intimately intertwined with tumor microenvironment (TME), fostering a symbiotic relationship propelling cancer progression. However, the interaction between cancer cells and tumor-associated macrophages (TAMs) in urothelial bladder cancer (UBC) remains poorly understood.
Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21
Authors: Jibo Han, Liming Lin, Zimin Fang, Bozhi Ye, Xue Han, Jiachen Xu, Binjiang Han, Julian Min, Jinfu Qian, Gaojun Wu, Yi Wang, Guang Liang
Journal: Theranostics (2024)

Cardiac hypertrophy is an important pathological basis for heart failure. Most physiological activities of cardiomyocytes are regulated by proteins and their post-translational modification. Deubiquitinating enzymes (DUBs) are involved in protein stability maintenance and closely related to myocardial hypertrophy. In this study, we aimed to clarify the regulatory role of a DUB, ubiquitin-specific peptidase 28 (USP28), in cardiac hypertrophy and explore the molecular mechanism behind.
Tumor-derived extracellular vesicles convey solute transporters to induce bioenergetic dependence shift contributing to treatment resistance
Authors: Jayshree Hirpara, Win Lwin Thuya, Sok-Hwee Cheow, Kanishka Fernando, Jie Qing Eu, Lingzhi Wang, Andrea Li-Ann Wong, Eliza Li Shan Fong, Azhar Bin Ali, Ling-Wen Ding, Wu Zhuoran, Yaw-Chyn Lim, Shazib Pervaiz, Boon-Cher Goh
Journal: Theranostics (2024)

Growing evidence points to the tumor microenvironment's role in developing drug resistance. A key element of this microenvironment is inter-cellular communication, which includes the release of membrane-encapsulated vesicles containing various cargo, known as extracellular vesicles (EVs). Understanding how EVs contribute to acquired resistance holds significant clinical implications.
Targeted sonogenetic modulation of GABAergic interneurons in the hippocampal CA1 region in status epilepticus
Authors: Tao Xu, Dandan Tan, You Wang, Chen Gong, Jinxian Yuan, Xiaolan Yang, Yuetao Wen, Yuenan Ban, Minxue Liang, Yaqin Hu, Yang Cao, Yangmei Chen, Haitao Ran
Journal: Theranostics (2024)

Sonogenetics is an advanced ultrasound-based neurostimulation approach for targeting neurons in specific brain regions. However, the role of sonogenetics in treating status epilepticus (SE) remains unclear. Here, we aimed to investigate the effects of ultrasound neurostimulation and MscL-G22S (a mechanosensitive ion channel that mediates Ca
Tumor-derived EV miRNA signatures surpass total EV miRNA in supplementing mammography for precision breast cancer diagnosis
Authors: Young Kim, Jee Ye Kim, Sol Moon, Hyojung Lee, Suji Lee, Joon Ye Kim, Min Woo Kim, Seung Il Kim
Journal: Theranostics (2024)

With the rising global incidence and mortality rates of breast cancer, early diagnosis is becoming increasingly crucial. The World Health Organization (WHO) recommends mammography as a primary screening tool. However, despite its clinical benefits, mammography has potential risks including radiation exposure, unnecessary follow-up, and overdiagnosis due to false positives, particularly in cases of early cancer or dense breast tissue. In this study, we aimed to address these concerns by introducing an innovative diagnostic method that employs circulating biomarkers to enhance the existing screening techniques
Preclinical pharmacology of patient-derived extracellular vesicles for the intraoperative imaging of tumors
Authors: Alessandro Villa, Daniela Crescenti, Zemira De Mitri, Elisabetta Crippa, Silvia Rosa, Nicoletta Rizzi, Fereshteh Shojaei-Ghahrizjani, Monica Rebecchi, Simona Vincenti, Francesca Selmin, Electra Brunialti, Nicolò Simonotti, Marianna Maspero, Michele Dei Cas, Camilla Recordati, Saverio Paltrinieri, Alessia Giordano, Rita Paroni, Margherita Galassi, Vito Ladisa, Flavio Arienti, Francesco Cilurzo, Vincenzo Mazzaferro, Paolo Ciana
Journal: Theranostics (2024)

Extracellular vesicles (EVs) derived from the plasma of oncological patients exhibit significant tumor-targeting properties, unlike those from healthy individuals. We have previously shown the feasibility of formulating the near-infrared (NIR) fluorescent dye indocyanine green (ICG) with patient-derived extracellular vesicles (PDEVs) for selective delivery to neoplastic tissue. This staining protocol holds promise for clinical application in intraoperative tumor margin imaging, enabling precise neoplastic tissue resection. To this end, we propose the ONCOGREEN protocol, involving PDEV isolation, ICG loading, and reinfusion into the same patients.
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer
Authors: Melissa Crabbé, Tomas Opsomer, Koen Vermeulen, Maarten Ooms, Charlotte Segers
Journal: Theranostics (2024)

Ovarian cancer is the most common gynecological malignancy worldwide with the highest mortality. This low survival rate can be attributed to the fact that symptoms arise only at an advanced disease stage, characterized by a (micro)metastatic spread across the peritoneal cavity. Radiopharmaceuticals, composed of a targeting moiety coupled with either a diagnostic or therapeutic radionuclide, constitute a relatively underexplored theranostic approach that may improve the current standard of care. Efficient patient stratification, follow-up and treatment are several caveats that could be addressed with theranostics to improve patient outcomes. So far, the bulk of research is situated and often halted at the preclinical level, employing murine models of primary and metastatic peritoneal disease that do not necessarily provide an accurate representation of the disease heterogeneity, (intrinsic) drug resistance or the complex physiological interactions with the tumor microenvironment. Radioimmunoconjugates with therapeutic α- and electron-emitting radionuclides have been the prevailing standard, targeting a myriad of cell-membrane markers that are expressed in the various heterogeneous histological subtypes of ovarian cancer. Evidently, several hurdles exist within preclinical research that are potentially withholding these agents from advancing into clinical practice. On the other hand, the field of nuclear medicine has also seen significant innovation to address shortcomings related to target/ligand identification, preclinical research models, radiochemistry, radiopharmacy and dosimetry, as outlined in this review. Altogether, theranostics hold great promise to answer an unmet medical need for ovarian cancer.
Biomineralized <i>in situ</i> catalytic nanoreactor integrated microneedle patch for on demand immunomodulator supply to combat psoriasis
Authors: Xiaodie Li, Minglong Chen, Xinni He, Jinghang Cong, Wanchen Zhao, Yanping Fu, Chao Lu, Chuanbin Wu, Xin Pan, Guilan Quan
Journal: Theranostics (2024)

The endogenous immunomodulator adenosine (ADO) was expected to be potentialized as an efficacious mediator to combat psoriasis. However, its efficacy is severely hindered by its poor metabolic stability and insufficient accumulation at the dermatological lesions.
Targeting the smooth muscle cell Keap1-Nrf2-GSDMD-pyroptosis axis by cryptotanshinone prevents abdominal aortic aneurysm formation
Authors: Jiaojiao Wang, Weile Ye, Jiami Zou, Pinglian Yang, Mei Jin, Zhihua Zheng, Chunhong Zhou, Wanlu Qiu, Jing Lu, Chengzhi Li, Shuai Guo, Yiming Xu, Zunnan Huang, Peiqing Liu, Zhiping Liu
Journal: Theranostics (2024)

: Abdominal aortic aneurysm (AAA) is an inflammatory, fatal aortic disease that currently lacks any effective drugs. Cryptotanshinone (CTS) is a prominent and inexpensive bioactive substance derived from
A novel ferroptosis inhibitor, Thonningianin A, improves Alzheimer's disease by activating GPX4
Authors: Yuanyuan Yong, Lu Yan, Jing Wei, Chi Feng, Lu Yu, Jianming Wu, Minsong Guo, Dongsheng Fan, Chonglin Yu, Dalian Qin, Xiaogang Zhou, Anguo Wu
Journal: Theranostics (2024)

Ferroptosis, a recently unveiled iron-dependent form of cellular demise, has emerged as a pivotal process contributing to the pathology of Alzheimer's Disease (AD). Glutathione Peroxidase 4 (GPX4), a vital defense mechanism countering ferroptosis by nullifying lipid peroxides and maintaining cellular redox equilibrium, has garnered significant attention in AD. Thus, identifying ferroptosis inhibitors to target GPX4 activation may help mitigate neuronal damage and impede AD progression.
Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles
Authors: Liang Liu, Ran Wang, Aogesi Alifu, Yong Xiao, Yong Liu, Chunfa Qian, Mengjie Zhao, Xianglong Tang, Yandong Xie, Yan Shi, Yuanjie Zou, Hong Xiao, Kun Yang, Hongyi Liu
Journal: Theranostics (2024)

M2-like tumor-associated macrophages (TAMs) promote the malignant progression of glioblastomas. However, the mechanisms responsible for this phenomenon remain unclear.
Whole-body fluorescence cryotomography identifies a fast-acting, high-contrast, durable contrast agent for fluorescence-guided surgery
Authors: Augustino V Scorzo, Brook K Byrd, Caleb Y Kwon, Rendall R Strawbridge, Kimberley S Samkoe, P Jack Hoopes, Keith D Paulsen, David W Roberts, Scott C Davis
Journal: Theranostics (2024)

Imaging of tumor-specific fluorescent contrast agents to guide tumor removal has been shown to improve outcomes and is now standard practice for some neurosurgical procedures. However, many agents require administration hours before surgery, a practical challenge, and may exhibit inconsistent concordance with contrast-enhanced MRI (CE-MRI), the current standard for diagnosing and guiding glioma removal. A fluorescent agent that accurately marks tumor shortly after administration and is otherwise similar to CE-MRI would help overcome these shortcomings.
DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma
Authors: Jingchun Wang, Yu Chen, Yanquan Xu, Jiangang Zhang, Shuai Yang, Yu Zhou, Juan Lei, Ran Ren, Yang Chen, Huakan Zhao, Yongsheng Li, Shiming Yang
Journal: Theranostics (2024)

The introduction of combination therapy utilizing tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors for advanced hepatocellular carcinoma (HCC) has significantly altered the management of affected patients. However, the absence of predictive biomarkers to identify those who would derive the greatest benefit from this combination therapy underscores the necessity for further enhancements in its efficacy.
Low hepatic artery blood flow mediates NET extravasation through the regulation of PIEZO1/SRC signaling to induce biliary complications after liver transplantation
Authors: Hongqiang Yu, Yujun Zhang, Ling Shuai, Cong Peng, Changchun Zhao, Yan Jiang, Ling Yao, Jiejuan Lai, Zhiyu Chen, Leida Zhang, Xiang Xiong, Xiaojun Wang
Journal: Theranostics (2024)

Biliary complications after liver transplantation persistently affect patient prognosis and graft survival. Neutrophil-mediated immune injury is an important factor leading to biliary injury. However, the mechanism by which neutrophils reach the periphery of the bile duct and further mediate bile duct injury is not fully understood.
Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy
Authors: Yifang Liao, Chenchen Zhao, Yuanwei Pan, Yiming Guo, Lujie Liu, Jicheng Wu, Yunjiao Zhang, Lang Rao, Qi Li
Journal: Theranostics (2024)

Inducing immunogenic cell death (ICD) is a promising strategy to enhance immune responses for immune checkpoint blockade (ICB) therapy, but the lack of a simple and effective platform to integrate ICD and ICB therapy limits their clinical application.
Lactoferrin docking NIR-II cyanine dye as a potentiated phototheranostic for synchronous multimodal bioimaging and tumor photo-immunotherapy
Authors: Lifeng Hang, Haijian Li, Meng Li, Yiqiang Sun, Wenjiao Wu, Laiping Fang, Yanzhao Diao, Hong Qu, Tao Zhang, Shumei Li, Guihua Jiang
Journal: Theranostics (2024)

A promising dye for phototheranostics, IR-1048 is a near-infrared region II (NIR-II) cyanine dye that exhibits exceptional optical characteristics in NIR-II spectrum. Unfortunately, the biological applications of IR-1048 are challenged by its hydrophobic nature, the formation of face-to-face stacked dimeric aggregates (H-aggregates) that result in pronounced spectral blue shifts, and issues related to fluorescence quenching.
Induction of ER stress-mediated apoptosis through SOD1 upregulation by deficiency of CHI3L1 inhibits lung metastasis: Erratum
Authors: Ji Eun Yu, In Jun Yeo, Seung Sik Yoo, Sung-Hyun Kim, Dong Ju Son, Jaesuk Yun, Sang-Bae Han, Jin Tae Hong
Journal: Theranostics (2024)

[This corrects the article DOI: 10.7150/thno.82898.].
Hypothalamic P62 (SQSTM1) regulates energy balance by modulating leptin signaling
Authors: Shan Yang, Yang Li, Mingyuan Tian, Wuquan Deng, Dongfang Liu, Chen Chen, Zhiming Zhu, Hongting Zheng, Gangyi Yang, Ling Li, Mengliu Yang
Journal: Theranostics (2024)

The multifaceted functions of p62 (SQSTM1) are increasingly recognized, but its role in hypothalamic metabolism-associated neurons for energy balance has yet to be elucidated.
Macrophage membrane‒biomimetic nanoparticles target inflammatory microenvironment for epilepsy treatment
Authors: Chao Geng, Xinghui Ren, Peipei Cao, Xiaoqi Chu, Penghu Wei, Quanlei Liu, Yongchang Lu, Bin Fu, Wenyou Li, Yuhao Li, Guoguang Zhao
Journal: Theranostics (2024)

The clinical treatment of epilepsy is faced with challenges. On the one hand, the effectiveness of existing antiepileptic drugs (AEDs) is limited by the blood‒brain barrier (BBB); on the other hand, changes in the inflammatory microenvironment during epileptogenesis are often neglected.
Intracalvariosseous administration of donepezil microspheres protects against cognitive impairment by virtue of long-lasting brain exposure in mice
Authors: Ji Hee Kang, Jin-Kyoung Yang, Kyo Hee Cho, O Hyun Lee, Hayoon Kwon, Sun Yeou Kim, Sehoon Kim, Young Tag Ko
Journal: Theranostics (2024)

Recent studies have demonstrated the direct connections between the skull bone marrow, meninges, and brain. In an effort to explore these connections for the purpose of brain drug delivery, we previously proposed the direct application of CNS drugs into the diploic space between the outer and inner cortex of the skull, namely, intracalvariosseous administration (ICO). It was successfully demonstrated that small molecular to large colloidal drugs can readily reach the brain after ICO in mice and rabbits. Here, we report that a single ICO of donepezil microspheres protects cognitive impairment in Alzheimer mouse models over a month-long period.
PET imaging of CXCR4 expression using [<sup>18</sup>F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors
Authors: Kai Cheng, Shijie Wang, Tianxin Liu, Jinli Pei, Shasha Wang, Jingru Liu, Kunlong Zhao, Yuxi Luo, Shengnan Xu, Jinming Yu, Jie Liu
Journal: Theranostics (2024)

C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for the diagnosis and treatment of cancers. Here, we aimed to develop a new CXCR4-targeted PET tracer, and to investigate the translational potential for noninvasive imaging of CXCR4 expression in various cancer entities through preclinical and pilot clinical studies.
Diagnostic and surveillance testing capability for mpox in the EU/EEA, September 2024
Authors: Nina Lagerqvist, Jessica Beser, Tamás Bakonyi, Céline M Gossner, Daniel Palm
Journal: Eurosurveillance (2024)

In response to the increasing number of mpox cases caused by monkeypox virus (MPXV) clade I in the African continent and the first reported travel-related clade Ib case of mpox in EU/EEA, the European Centre for Disease Prevention and Control surveyed national capability for detection and characterisation of MPXV in the EU/EEA. The results showed high level of capability for case confirmation by PCR, alongside molecular typing methods for identification of MPXV clades and/or clade I subclades within the EU/EEA.
Sweden surpasses the UNAIDS 95-95-95 target: estimating HIV-1 incidence, 2003 to 2022
Authors: Erik Lundgren, Macauley Locke, Ethan Romero-Severson, Mira Dimitrijevic, Maria Axelsson, Emmi Andersson, Christina Carlander, Johanna Brännström, Hans Norrgren, Fredrik Mansson, Olof Elvstam, Magnus Gisslén, Lisa Fohlin, Anders Sönnerborg, Jan Albert, Thomas Leitner
Journal: Eurosurveillance (2024)

Background Sweden reached the UNAIDS 90–90–90 target in 2015. It is important to reassess the HIV epidemiological situation due to ever-changing migration patterns, the roll-out of PrEP and the impact of the COVID-19 pandemic. Aim We aimed to assess the progress towards the UNAIDS 95–95–95 targets in Sweden by estimating the proportion of undiagnosed people with HIV (PWHIV) and HIV incidence trends. Methods We used routine laboratory data to inform a biomarker model of time since infection. When available, we used previous negative test dates, arrival dates for PWHIV from abroad and transmission modes to inform our incidence model. We also used data collected from the Swedish InfCareHIV register on antiretroviral therapy (ART). Results The yearly incidence of HIV in Sweden decreased after 2014. In part, this was because the fraction of undiagnosed PWHIV had decreased almost twofold since 2006. After 2015, three of four PWHIV in Sweden were diagnosed within 1.9 and 3.2 years after infection among men who have sex with men and in heterosexual groups, respectively. While 80% of new PWHIV in Sweden acquired HIV before immigration, they make up 50% of the current PWHIV in Sweden. By 2022, 96% of all PWHIV in Sweden had been diagnosed, and 99% of them were on ART, with 98% virally suppressed. Conclusions By 2022, about half of all PWHIV in Sweden acquired HIV abroad. Using our new biomarker model, we assess that Sweden has reached the UNAIDS goal at 96–99–98.
Letter to the Editor: First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023
Authors: Florian Heger, Alexander Indra
Journal: Eurosurveillance (2024)

Preview this article: Letter to the Editor: First detection of a Mycobacterium tuberculosis XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/29/42/eurosurv-29-42-6-1.gif
Epidemiological analysis of confirmed mpox cases, Burundi, 3 July to 9 September 2024
Authors: Alexis Nizigiyimana, Francois Ndikumwenayo, Sarah Houben, Martin Manirakiza, Monique van Lettow, Laurens Liesenborghs, Placide Mbala-Kingebeni, Anne W Rimoin, Isaac I Bogoch, Jason Kindrachuk
Journal: Eurosurveillance (2024)

We analysed mpox cases in Burundi from July to September 2024, following the introduction of Clade Ib virus. Of 607 samples from the whole population of suspected cases, 154 were PCR-positive, of whom 85 were children under 15 years, with a higher proportion of female children testing positive. Geographical analysis demonstrates case concentration in Bujumbura Mairie (91/154). Age- and sex-specific interventions, as well as community engagement, are important for outbreak containment, as are targeted public health strategies in Burundi.